U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend

Article highlights Eli Lilly as a GLP-1 leader with strong sales in Mounjaro, Zepbound, and Foundayo, supported by a deep pipeline including phase 3 retatrutide that shows efficacy rivaling bariatric procedures. It also frames Intuitive Surgical’s robotic-assisted surgery franchise as benefiting from underpenetrated RAS, da Vinci 5 uptake (launched in 2024), and recurring instrument revenue, though it notes tariff headwinds and potential competitive pressure. Net takeaway: constructive long-term growth tailwinds for both stocks, without specific near-term financial figures.

Analysis

LLY is the cleaner secular winner, but the market is already paying for that optionality; the key question is not whether GLP-1 demand exists, but whether utilization can keep outpacing manufacturing, payer pushback, and competitor normalization over the next 1-3 quarters. The second-order winner is likely not another branded obesity name, but the broader obesity ecosystem: employers, pharmacy benefit managers, and bariatric/surgical substitutes all face pressure if oral/next-gen agents broaden access and reduce friction. NVO is the most obvious relative loser if share shifts remain U.S.-led, but the more dangerous risk for both GLP-1 leaders is that pricing power erodes faster than volume scales.

ISRG’s moat is less about the robot and more about the installed base producing recurring instrument pull-through; that makes procedure growth the real earnings lever. Near term, tariffs and hospital CapEx caution can compress margins and delay placements, but over 6-18 months the bigger issue is whether rival systems force pricing concession or just fragment mindshare while ISRG retains utilization leadership. JNJ is the main strategic competitor to watch, but the stock-level implication is that ISRG can absorb modest competitive noise as long as procedure growth stays mid-teens and margins don’t get permanently reset.

Contrarian takeaway: this is a quality-growth basket where consensus is likely underestimating how much of the good news is already embedded in valuation. For LLY, the thesis breaks if payer coverage tightens or supply ramps slower than demand; for ISRG, it breaks if tariff costs persist while procedure growth slows below expectations. Over the next few months, the cleaner setup is relative-value rather than outright chase: own the leader only if fundamentals keep surprising, otherwise the risk is multiple compression even on solid operating numbers.

Key Decisions for Investors

• Long LLY / short NVO as a 1-3 month relative-value pair: expresses share gain and pipeline dominance without relying on sector multiple expansion; exit if NVO U.S. prescription trends re-accelerate or LLY guidance implies slower volume growth.
• Buy ISRG on tariff-related weakness only, not strength; 3-6 month horizon with a focus on procedure volume and gross margin resilience. Falsifier: procedure growth decelerates materially or hospitals push out system purchases.
• If chasing upside in LLY, prefer call spreads over stock for a 3-6 month catalyst window to cap valuation risk; the trade only works if the next earnings print confirms sustained demand and supply normalization.
• Avoid long-only exposure to broad healthcare ETFs (XLV) as the article reinforces winner concentration: performance is likely to be driven by LLY/ISRG at the top while most peers lag.
• Watch JNJ as a secondary beneficiary/competitive hedge: if robotic surgery adoption broadens but ISRG pricing holds, JNJ is the logical short on relative share-take, but only after evidence of durable da Vinci 5 install growth.